Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus sorafenib or lenvatinib as first-line treatment for advanced hepatocellular carcinoma
jRCT2080225035Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised trial in hepatocellular carcinoma (HCC) comparing Nivolumab + ipilimumab, Sorafenib and Lenvatinib (3 arms). Started Jan 2020; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080225035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225035.